MedTrace Logo

MR Imaging Biomarkers of Disease Response to ECT (Electroconvulsive Therapy) in Depression

NCT02044289 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2016-02-03

No results posted yet for this study

Summary

The purpose of this study is to (a) measure how brain structure, metabolism (how the brain uses energy), and function predict response to electroconvulsive therapy (ECT) for treatment of depression; and (b) measure how ECT changes brain metabolism and function. We will ask you to undergo magnetic resonance imaging (MRI) at three sessions: (1) prior to your first ECT therapy session, (2) after having 4-6 ECT therapy sessions, and (3) approximately two months following your first ECT therapy sessions.

Conditions

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Ryan T Fitzgerald, MD · University of Arkansas

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02044289 on ClinicalTrials.gov